Utilization of genetic tests: Analysis of gene-specific billing in Medicare claims data

Genetics in Medicine

Volumn 19, Issue 8, 2017, Pages 890-899

  Lynch, Julie A ^a,b   Berse, Brygida ^a,b,c   Dotson, W David ^d   Khoury, Muin J ^d   Coomer, Nicole ^a   Kautter, John ^a  

^a RTI INTERNATIONAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Billing code; Genomic testing; Hospital referral region; Medicare; Pharmacogenetics

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; CLOPIDOGREL; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; NEUROLEPTIC AGENT; OPIATE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; WARFARIN; TUMOR MARKER;

AGED; ALASKA; ARTICLE; BILLING AND CLAIMS; BREAST CANCER; CHRONIC DRUG ADMINISTRATION; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DIAGNOSTIC TEST; DISORDERS OF LIPID METABOLISM; DRUG USE; FEMALE; GENE MUTATION; GENETIC SCREENING; GENETIC VARIATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MEDICAL INFORMATION; MEDICAL SOCIETY; MEDICARE; MISSISSIPPI; MUTATIONAL ANALYSIS; PATIENT ASSESSMENT; PERSONALIZED MEDICINE; PHARMACOGENETIC TESTING; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; ECONOMICS; GENETIC PREDISPOSITION; INSURANCE; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; STATISTICS AND NUMERICAL DATA; UNITED STATES; UTILIZATION;

AGED; BIOMARKERS, TUMOR; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INSURANCE CLAIM REPORTING; LUNG NEOPLASMS; MALE; MEDICARE; MIDDLE AGED; PRECISION MEDICINE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 85026843441     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2016.209     Document Type: Article

References (40)

1. The White House Office of the Press Secretary. Fact sheet: President Obama's Precision Medicine Initiative. 2015. https://www.whitehouse.gov/the-pressoffice/ 2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative. Accessed 27 October 2015.
2. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793-795.
3. US Preventive Services Task Force. The Guide to Clinical Preventive Services. 2014. http://www.uspreventiveservicestaskforce.org/Page/Name/tools-andresources- for-better-preventive-care. Accessed 14 December 2015.
4. National Comprehensive Cancer Network. NCCN Biomarkers Compendium. 2015. http://www.nccn.org/professionals/biomarkers/default.aspx. Accessed 17 December 2015.
5. Joyner MJ. "Moonshot" medicine will let us down. New York Times, 29 January 2015. http://www.nytimes.com/2015/01/29/opinion/moonshot-medicine-willlet- us-down.html?-r=0. Accessed 29 July 2016.
6. Graber C. The problem with precision medicine. New Yorker, 5 February 2015. http://www.newyorker.com/tech/elements/problem-precision-medicine. Accessed 29 July 2016.
7. Rubin R. Precision medicine: the future or simply politics? JAMA 2015;313:1089-1091.
8. Duffy DJ. Problems, challenges and promises: perspectives on precision medicine. Brief Bioinform 2016;17:494-504.
9. Lam TK, Chang CQ, Rogers SD, Khoury MJ, Schully SD. Evolution of the "drivers" of translational cancer epidemiology: analysis of funded grants and the literature. Am J Epidemiol 2015;181:451-458.
10. Kautter J, Lynch J, Coomer N, Berse B, Leahy S. Design and implementation support for the treatment of certain complex diagnostic laboratory tests demonstration. Report prepared for Centers for Medicare & Medicaid Services. 2015.
11. Carreyrou J. Health diagnostic laboratory CEO resigns. Wall Street Journal, 23 September 2014. http://www.wsj.com/articles/health-diagnostic-laboratoryceo- to-step-down-1411500521. Accessed 23 September, 2014.
12. American Medical Association. CPT. http://www.ama-assn.org/ama/pub/ physician-resources/solutions-managing-your-practice/coding-billing-insurance/ cpt.page. Accessed 2 October 2015.
13. Zuvekas SH, Cohen JW. Fee-for-service, while much maligned, remains the dominant payment method for physician visits. Health Aff (Millwood) 2016;35:411-414.
14. Kaiser Family Foundation. State Health Facts. Medicare. 2015. http://kff.org/ state-category/medicare/. Accessed 8 November 2016.
15. Agency for Healthcare Research and Quality. Clinical Classifications Software (CCS) for ICD-9-CM. 2016. https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ ccs.jsp. Accessed 28 July 2016.
16. Lynch JA, Khoury MJ, Borzecki A, et al. Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research. Genet Med 2013;15:630-638.
17. National Institutes of Health. GTR: Genetic Testing Registry. 2015. http://www. ncbi.nlm.nih.gov/gtr/. Accessed 27 October 2015.
18. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 2013;17:165-184.
19. Scott SA, Sangkuhl K, Stein CM, et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013;94:317-323.
20. Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med 2015;25:33-41.
21. O'Donnell PH, Ratain MJ. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol 2012;6:251-259.
22. Kang SJ, Lee C, Kruzliak P. Effects of serum bilirubin on atherosclerotic processes. Ann Med 2014;46:138-147.
23. Igbokwe A, Lopez-Terrada DH. Molecular testing of solid tumors. Arch Pathol Lab Med 2011;135:67-82.
24. Pfeifer JD, Zehnbauer B, Payton J. The changing spectrum of DNA-based specimen provenance testing in surgical pathology. Am J Clin Pathol 2011;135:132-138.
25. American Cancer Society. Cancer Facts and Figures. 2014. http://www.cancer. org/research/cancerfactsstatistics/index. Accessed 1 September 2014.
26. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Statistics Review (CSR) 1975-2013. http://seer.cancer. gov/csr/1975-2013/. Accessed 7 July 2016.
27. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41:89-295.
28. Centers for Medicare & Medicaid Services. Local Coverage Determination (LCD): CYP2C19, CYP2D6, CYP2C9, and VKORC1 Genetic Testing (L35698). Baltimore, MD, 2015.
29. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-2022.
30. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group. MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288:2023-2031.
31. Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med 2013;15:153-156.
32. Berglund L, Brunzell JD, Goldberg AC, et al.; Endocrine society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:2969-2989.
33. Lockwood C, Wendel G; Committee on Practice Bulletins - Obstetrics. Practice bulletin no. 124: inherited thrombophilias in pregnancy. Obstet Gynecol 2011;118:730-740.
34. Centers for Medicare & Medicaid Services. Draft LCD for Biomarkers Overview DL33638. https://localcoverage.cms.gov/mcd-archive/viewlcd.asp?lcd- id=33637&lcd-version=16. Accessed 9 May 2016.
35. Petrilli CM, Heidemann L, Mack M, Durance P, Chopra V. Inpatient inherited thrombophilia testing. J Hosp Med 2016;11:801-804.
36. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-859.
37. Centers for Medicare & Medicaid Services. Draft LCD for Biomarkers for Oncology (DL33138). http://localcoverage.cms.gov/mcd-archive/search.asp. Accessed 7 July 2016.
38. Kurian AW, Ford JM. Multigene panel testing in oncology practice: how should we respond? JAMA Oncol 2015;1:277-278.
39. Moyer VA; U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160:271-281.
40. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med 2011;13:67-76.